Business Context and Reporting Period
Company: Evogene Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 25, 2022
Reporting Period: Month of August 2022
Context: The filing announces a corporate governance update regarding the company's listing status on the Nasdaq stock exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of regulatory compliance rather than a financial statement.
Material Changes
- Nasdaq Compliance: Evogene Ltd. regained compliance with the Nasdaq minimum closing bid price rule.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) confirming the restoration of compliance with Nasdaq listing standards.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the text of this filing.
Guidance: No financial guidance or future outlook is provided in this document.
Investor Verification Checklist
- Verify the specific date and details of the Nasdaq compliance restoration in the attached press release (Exhibit 99.1).
- Confirm the current stock price to ensure continued compliance with the minimum bid price rule.
- Review subsequent filings for any financial updates, as this Form 6-K contains no financial data.